Evidence map›Paper›PMID 34795873›Full record

ArticleACS medicinal chemistry letters2021

Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics.

Christopher J Fritschi, Shuaiyi Liang, Mohammadjavad Mohammadi, Saumya Anang, Francesca Moraca, Junhua Chen, Navid Madani, Joseph G Sodroski, Cameron F Abrams, Wayne A Hendrickson and 1 more

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Christopher J FritschiDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Shuaiyi LiangDepartment of Biochemistry and Molecular Biophysics and Department of Physiology and Cellular Biophysics, Columbia University, New York, New York 10032, United States.
Mohammadjavad MohammadiDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania 19104, United States.
Saumya AnangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Microbiology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Francesca MoracaDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania 19104, United States.ORCID https://orcid.org/0000-0003-0248-9834
Junhua ChenDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Navid MadaniDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Microbiology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Joseph G SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Microbiology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Cameron F AbramsDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania 19104, United States.ORCID https://orcid.org/0000-0002-1240-0816
Wayne A HendricksonDepartment of Biochemistry and Molecular Biophysics and Department of Physiology and Cellular Biophysics, Columbia University, New York, New York 10032, United States.
Amos B SmithDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.ORCID https://orcid.org/0000-0002-1712-8567
Drexel University · USHarvard University · USUniversity of Pennsylvania · USColumbia University · US

Funding

Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01AI150471 · NIAID · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M · 2019 to 2022
$7.8M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR33AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$1.6M
NIAID NIH HHS P01 AI150471NIAID NIH HHS R33 AI129017
6 · The paper itself

Abstract

The design and synthesis of butyl chain derivatives at the indane ring 3-position of our lead CD4-mimetic compound BNM-III-170 that inhibits human immunodeficiency virus (HIV-1) infection are reported. Optimization efforts were guided by crystallographic and computational analysis of the small-molecule ligands of the Phe43 cavity of the envelope glycoprotein gp120. Biological evaluation of

Identifiers

PMID34795873
PMCPMC8591726
OpenAlexW3210438901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.